• Phathom Pharmaceuticals moved to intervene in BDR Pharmaceuticals' lawsuit against the FDA to defend VOQUEZNA's regulatory exclusivity.
• BDR challenges the FDA's June 6, 2025, decision recognizing 10 years of new chemical entity exclusivity through May 3, 2032.
• The FDA opened public comments on legal and regulatory issues raised in the litigation, with submissions due November 23, 2026.
• Saba Ilac Sanayii Ve Ticaret AS intends to seek consolidation of its related case with BDR's lawsuit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260400PRIMZONEFULLFEED9852790) on October 26, 2026, and is solely responsible for the information contained therein.